Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

2.6K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.6K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

919
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
919

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimising the workflow for infant ABO blood typing: The role of automated analyser and a manual reflex protocol.

Transfusion medicine (Oxford, England)·2026
Same author

Identification of Poor Prognostic Markers in Triple-Negative Breast Cancer Using Whole Exome Sequencing.

Journal of breast cancer·2025
Same author

Reinterpreting National Whole-genome Sequencing Data: Lessons from the First Korean Pilot Study.

Annals of laboratory medicine·2025
Same author

Laboratory approaches in desensitization for ABO-incompatible transplantation.

Clinical transplantation and research·2025
Same author

Current practices in peripheral blood stem cell processing and cryopreservation: a nationwide survey of Korean transplant centers.

Blood research·2025
Same author

Evaluating the appropriateness of fresh frozen plasma transfusions in two tertiary teaching hospitals.

Transfusion medicine (Oxford, England)·2025

Related Experiment Video

Updated: Dec 11, 2025

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K

Platelet Inventory Management Program: Development and Practical Experience.

Hyun-Ji Lee1, Seung-Hwan Oh1, Su-Yeon Jo1

  • 1Department of Laboratory Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.

Annals of Laboratory Medicine
|August 25, 2020
PubMed
Summary
This summary is machine-generated.

A new platelet (PLT) inventory management program improved transfusion efficiency. This system reduced PLT discard rates by optimizing allocation based on expiration dates, ensuring better patient care.

Keywords:
ApheresisDiscard rateExpiration dateInventory programPlatelet concentratesTransfusions

More Related Videos

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.3K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.2K

Related Experiment Videos

Last Updated: Dec 11, 2025

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.4K
Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.3K
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

14.2K

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Healthcare Management

Background:

  • Platelet (PLT) transfusions are critical for patients with bleeding risks.
  • A significant delay exists between PLT product request and availability due to manufacturing and testing.
  • This supply-demand gap results in high PLT discard rates from excess inventory.

Purpose of the Study:

  • To develop and implement a PLT inventory management program.
  • To improve the efficiency of PLT transfusion supply to patients.
  • To reduce the rate of PLT product discard.

Main Methods:

  • Analyzed PLT concentrates and apheresis products over two periods (May 2015-Jan 2020).
  • Developed a program to manage PLT inventories and transfusion patient needs.
  • Integrated blood type, product type, and remaining efficacy for optimized PLT preparation and transfer.

Main Results:

  • The overall PLT concentrate discard rate decreased from 3.07% to 2.41% post-program implementation (P<0.001).
  • The discard rate specifically due to expiration was dramatically reduced from 3.81% to 0.14% (P<0.001).

Conclusions:

  • The developed program effectively guides PLT preparation allocation.
  • Utilizing PLT products before expiration is enhanced by the program.
  • Significant reduction in PLT product discard rates was achieved.